An educational resource of the Ocular Immunology and Uveitis Foundation

Massachusetts Eye Research and Surgery Institution
About Us Patient Information Medical Professionals Services

Low Vision | Our Medical Advisor | Member Guidelines | Ask Dr. Foster | Uveitis Glossary | Pars Planitis Forum | Contact Us

Home Page
    > Mike's Reading Corner
        > Long-term Risk of Malignancy Among Patients Treated with IMT
New Topic

<< Prev Topic | Next Topic >>
Author
Comment
Webmaster
Administrator
(11/17/08 11:07 pm)


Long-term Risk of Malignancy Among Patients Treated with IMT
Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence. Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Helzlsouer KJ.

PURPOSE:
To critically assess potentially carcinogenic effects of immunosuppressive therapy in the ocular inflammation setting.

DESIGN:
Focused evidence assessment.

METHODS:
Relevant publications were identified by MEDLINE and EMBASE queries and reference list searches.

RESULTS:
Extrapolation from transplant, rheumatology, skin disease, and inflammatory bowel disease cohorts to the ocular inflammation setting suggest that: 1) alkylating agents increase hematologic malignancy risk and cyclophosphamide increases bladder cancer risk, but less so with </=18 months' duration of therapy and hydration, respectively; 2) calcineurin inhibitors and azathioprine probably do not increase total cancer risk to a detectable degree, except perhaps some other risk factors (uncommon in ocular inflammation patients) might interact with the former to raise risk; 3) tumor necrosis factor (TNF) inhibitors may accelerate diagnosis of cancer in the first six to 12 months, but probably do not increase long-term cancer risk; and 4) changes in risk with methotrexate, mycophenolate mofetil, and daclizumab appear negligible, although nontransplant data are limited for the latter agents. Immunosuppression in general may increase skin cancer risk in a sun exposure-dependent manner.

CONCLUSION:
Use of alkylating agents for a limited duration seems justifiable for severe, vision-threatening disease, but otherwise cancer risk may be a relevant constraint on use of this approach. Antimetabolites, daclizumab, TNF inhibitors, and calcineurin inhibitors probably do not increase cancer risk to a degree that outweighs the expected benefits of therapy. Monitoring for skin cancer may be useful for highly sun-exposed patients. Data from ocular inflammation patients are needed to confirm the conclusions made in this analysis by extrapolation.

<< Prev Topic | Next Topic >>


Topic Control Image Topic Commands
Click to receive email notification of replies Click to receive email notification of replies
Click to stop receiving email notification of replies Click to stop receiving email notification of replies
jump to:

- Home Page - Mike's Reading Corner - Ocular Immunology and Uveitis Foundation, URL>>www.uveitis.org -

Low Vision Instructions | About Our Medical Advisor | Uveitis  Glossary | Office Directions  |  Contact Us



Powered By ezboard® Ver. 7.32
Copyright ©1999-2007 ezboard, Inc.